Early Childhood Infections Precede Development of Beta-cell Autoimmunity and Type 1 Diabetes in Children with HLA-conferred Disease Risk
Overview
Pediatrics
Affiliations
Background: The etiology of type 1 diabetes (T1D) is largely unknown. Infections and microbial exposures are believed to play a role in the pathogenesis and in the development of islet autoimmunity in genetically susceptible individuals.
Objective: To assess the relationships between early childhood infections, islet autoimmunity, and progression to T1D in genetically predisposed children.
Methods: Children with human leukocyte antigen (HLA)-conferred disease susceptibility (N=790; 51.5% males) from Finland (n = 386), Estonia (n = 322), and Russian Karelia (n = 82) were observed from birth up to the age of 3 years. Children attended clinical visits at the age of 3, 6, 12, 18, 24, and 36 months. Serum samples for analyzing T1D-associated autoimmune markers were collected and health data recorded during the visits.
Results: Children developing islet autoimmunity (n = 46, 5.8%) had more infections during the first year of life (3.0 vs 3.0, mean rank 439.1 vs 336.2; P = .001) and their first infection occurred earlier (3.6 vs 5.0 months; P = .005) than children with no islet autoimmunity. By May 2016, 7 children (0.9%) had developed T1D (progressors). Compared with non-diabetic children, T1D progressors were younger at first infection (2.2 vs 4.9 months; P = .004) and had more infections during the first 2 years of life (during each year 6.0 vs 3.0; P = .001 and P = .027, respectively). By 3 years of age, the T1D progressors had twice as many infections as the other children (17.5 vs 9.0; P = .006).
Conclusions: Early childhood infections may play an important role in the pathogenesis of T1D. Current findings may reflect either differences in microbial exposures or early immunological aberrations making diabetes-prone children more susceptible to infections.
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol.
Hummel S, Kassl A, Arnolds S, Achenbach P, Berner R, Casteels K Contemp Clin Trials Commun. 2025; 44:101434.
PMID: 39916680 PMC: 11799962. DOI: 10.1016/j.conctc.2025.101434.
Impact of Early-Life Microbiota on Immune System Development and Allergic Disorders.
Dera N, Kosinska-Kaczynska K, Zeber-Lubecka N, Brawura-Biskupski-Samaha R, Massalska D, Szymusik I Biomedicines. 2025; 13(1).
PMID: 39857705 PMC: 11762082. DOI: 10.3390/biomedicines13010121.
The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus.
Debuysschere C, Nekoua M, Alidjinou E, Hober D Nat Rev Endocrinol. 2024; 20(10):588-599.
PMID: 38890459 DOI: 10.1038/s41574-024-01004-9.
Zeller I, Weiss A, Arnolds S, Schutte-Borkovec K, Arabi S, von dem Berge T Infection. 2024; 52(6):2465-2473.
PMID: 38874748 PMC: 11621198. DOI: 10.1007/s15010-024-02312-y.
Infant liver biochemistry is different than current laboratory accepted norms.
Kolho K, Lahtiharju T, Merras-Salmio L, Pakarinen M, Knip M Eur J Pediatr. 2023; 182(12):5707-5711.
PMID: 37812243 PMC: 10746582. DOI: 10.1007/s00431-023-05248-x.